174 related articles for article (PubMed ID: 37406887)
1. Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation.
Marchegiani G; Pollini T; Burelli A; Han Y; Jung HS; Kwon W; Rocha Castellanos DM; Crippa S; Belfiori G; Arcidiacono PG; Capurso G; Apadula L; Zaccari P; Noia JL; Gorris M; Busch O; Ponweera A; Mann K; Demir IE; Phillip V; Ahmad N; Hackert T; Heckler M; Lennon AM; Afghani E; Vallicella D; Dall'Olio T; Nepi A; Vollmer CM; Friess H; Ghaneh P; Besselink M; Falconi M; Bassi C; Goh BK; Jang JY; Fernández-Del Castillo C; Salvia R
Gastroenterology; 2023 Oct; 165(4):1016-1024.e5. PubMed ID: 37406887
[TBL] [Abstract][Full Text] [Related]
2. "Trivial" Cysts Redefine the Risk of Cancer in Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Potential Target for Follow-Up Discontinuation?
Marchegiani G; Andrianello S; Pollini T; Caravati A; Biancotto M; Secchettin E; Bonamini D; Malleo G; Bassi C; Salvia R
Am J Gastroenterol; 2019 Oct; 114(10):1678-1684. PubMed ID: 31449158
[TBL] [Abstract][Full Text] [Related]
3. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of branch-duct intraductal papillary mucinous neoplasms with No change in first 5 Years of diagnosis.
Lee BS; Nguyen AK; Tekeste TF; Chang K; Girgis A; Adeyemo M; Hanna MS; Yao JF; Kwok KK; Giap AQ; Hunt GC; Chaya CT; Kao KT; Attam R; Ko A; Pio JR; Tovar S; Lim BS
Pancreatology; 2021 Jan; 21(1):144-154. PubMed ID: 33309223
[TBL] [Abstract][Full Text] [Related]
5. Optimal Surveillance Interval of Branch Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas.
Han Y; Kwon W; Lee M; Jung HS; Yun WG; Cho YJ; Chae YS; Fernández-Del Castillo C; Marchegiani G; Salvia R; Goh BKP; Lee WJ; Jang JY
JAMA Surg; 2024 Apr; 159(4):389-396. PubMed ID: 38231494
[TBL] [Abstract][Full Text] [Related]
6. Systematic review on surveillance for non-resected branch-duct intraductal papillary mucinous neoplasms of the pancreas.
Kazmi SZ; Jung HS; Han Y; Yun WG; Cho YJ; Lee M; Kwon W; Castillo CF; Del Chiaro M; Marchegiani G; Goh BKP; Hijioka S; Majumder S; Nakai Y; Shin A; Jang JY
Pancreatology; 2024 May; 24(3):463-488. PubMed ID: 38480047
[TBL] [Abstract][Full Text] [Related]
7. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
[TBL] [Abstract][Full Text] [Related]
8. Association of high-risk stigmata and worrisome features with advanced neoplasia in intraductal papillary mucinous neoplasms (IPMN): A systematic review.
Ohno E; Balduzzi A; Hijioka S; De Pastena M; Marchegiani G; Kato H; Takenaka M; Haba S; Salvia R
Pancreatology; 2024 Feb; 24(1):48-61. PubMed ID: 38161091
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic fat content may increase the risk of imaging progression in low-risk branch duct intraductal papillary mucinous neoplasm.
Kashiwagi K; Minami K; Seino T; Hirata K; Iwasaki E; Inoue N; Iwao Y; Kanai T
J Dig Dis; 2019 Oct; 20(10):557-562. PubMed ID: 31322828
[TBL] [Abstract][Full Text] [Related]
10. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.
Yan L; Siddiqui AA; Laique SN; Saumoy M; Kahaleh M; Yoo J; Kalra A; Mathew A; Sterling J; Rao R; Lieberman M; Cosgrove N; Sharaiha RZ
Minerva Gastroenterol Dietol; 2017 Mar; 63(1):50-54. PubMed ID: 27824244
[TBL] [Abstract][Full Text] [Related]
11. Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer.
Nguyen AH; Toste PA; Farrell JJ; Clerkin BM; Williams J; Muthusamy VR; Watson RR; Tomlinson JS; Hines OJ; Reber HA; Donahue TR
J Gastrointest Surg; 2015 Feb; 19(2):258-65. PubMed ID: 25373706
[TBL] [Abstract][Full Text] [Related]
12. Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer: multicentre study.
Tamburrino D; de Pretis N; Pérez-Cuadrado-Robles E; Uribarri-Gonzalez L; Ateeb Z; Belfiori G; Maisonneuve P; Capurso G; Vanella G; Petrone MC; Arcidiacono PG; Vaalavuo Y; Frulloni L; Dominguez-Muñoz JE; Deprez PH; Falconi M; Del Chiaro M; Crippa S; Laukkarinen J
Br J Surg; 2022 Jun; 109(7):617-622. PubMed ID: 35511697
[TBL] [Abstract][Full Text] [Related]
13. Long-term surveillance of branch-duct intraductal papillary mucinous neoplasms without worrisome or high-risk features.
Lattimore CM; Kane WJ; Subbarao S; Venitti C; Cramer CL; Turkheimer LM; Bauer TW; Turrentine FE; Zaydfudim VM
J Surg Oncol; 2023 Dec; 128(7):1087-1094. PubMed ID: 37530526
[TBL] [Abstract][Full Text] [Related]
14. Incidence and Prevalence of Intraductal Papillary Mucinous Neoplasms in Individuals With BRCA1 and BRCA2 Pathogenic Variant.
Shah I; Silva-Santisteban A; Germansky KA; Wadhwa V; Tung N; Huang DC; Kandasamy C; Mlabasati J; Bilal M; Sawhney MS
J Clin Gastroenterol; 2023 Mar; 57(3):317-323. PubMed ID: 35220378
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of intraductal papillary neoplasia of the pancreas (IPMN) under surveillance.
Johansson K; Kaprio T; Nieminen H; Lehtimäki TE; Lantto E; Haglund C; Seppänen H
Scand J Surg; 2022; 111(1):14574969221076792. PubMed ID: 35333109
[TBL] [Abstract][Full Text] [Related]
16. Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis.
Chhoda A; Singh S; Sheth AH; Grimshaw AA; Gunderson CG; Sharma P; Kunstman JW; Sharma A; Ahuja N; Gonda TA; Farrell JJ
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1430-1446. PubMed ID: 35568304
[TBL] [Abstract][Full Text] [Related]
17. International external validation of a stratification tool to identify branch-duct intraductal papillary mucinous neoplasms at lowest risk of progression.
Overbeek KA; van Leeuwen N; Tacelli M; Anwar MS; Yousaf MN; Chhoda A; Arcidiacono PG; Gonda TA; Wallace MB; Capurso G; Farrell JJ; Cahen DL; Bruno MJ
United European Gastroenterol J; 2022 Mar; 10(2):169-178. PubMed ID: 35199484
[TBL] [Abstract][Full Text] [Related]
18. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series.
Sahora K; Mino-Kenudson M; Brugge W; Thayer SP; Ferrone CR; Sahani D; Pitman MB; Warshaw AL; Lillemoe KD; Fernandez-del Castillo CF
Ann Surg; 2013 Sep; 258(3):466-75. PubMed ID: 24022439
[TBL] [Abstract][Full Text] [Related]
19. Higher Growth Rate of Branch Duct Intraductal Papillary Mucinous Neoplasms Associates With Worrisome Features.
Kolb JM; Argiriadi P; Lee K; Liu X; Bagiella E; Gupta S; Lucas AL; Kim MK; Kumta NA; Nagula S; Sarpel U; DiMaio CJ
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1481-1487. PubMed ID: 29535058
[TBL] [Abstract][Full Text] [Related]
20. Branch-duct intraductal papillary mucinous neoplasm (IPMN): Are cyst volumetry and other novel imaging features able to improve malignancy prediction compared to well-established resection criteria?
Pozzi Mucelli RM; Moro CF; Del Chiaro M; Valente R; Blomqvist L; Papanikolaou N; Löhr JM; Kartalis N
Eur Radiol; 2022 Aug; 32(8):5144-5155. PubMed ID: 35275259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
